Completed PHASE4 INTERVENTIONAL NCT00171522

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation

Sponsor: Novartis

Conditions Constipation

Interventions Tegaserod and Polyethylene Glycol 3350

Updated 6 times since 2017 Last updated: Mar 2, 2016 Started: May 31, 2005 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Constipation and is currently completed. Novartis leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bellbrook, United States , Boca Raton, United States , Boston, United States , Buena Park, United States , Hermitage, United States , Lake Jackson, United States , Margate City, United States , Omaha, United States , Oro Valley, United States , Phoenix, United States and 4 more locations